
Home » MEI Pharma acquires rights to Pathway drug candidate
MEI Pharma acquires rights to Pathway drug candidate
September 11, 2013
MEI Pharma, an oncology company focused on the clinical development of novel therapies for cancer, has acquired exclusive worldwide rights to the investigational drug candidate PWT143 from Pathway Therapeutics, a privately-held pharmaceutical company, for an undisclosed upfront payment with no future milestone or royalty obligations.
In preclinical studies, PWT143 has been found to be a potent and highly selective oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target shown to play a critical role in the proliferation and survival of hematologic cancer cells. MEI Pharma anticipates filing an IND application for PWT143 by the end of 2014.
Upcoming Events
-
14Apr